Analysts Set Pacira Pharmaceuticals Inc (PCRX) PT at $46.65

Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) have been assigned a consensus recommendation of “Hold” from the twenty-four analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $46.65.

PCRX has been the subject of several recent research reports. HC Wainwright set a $48.00 price objective on Pacira Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, May 3rd. Canaccord Genuity set a $34.00 price objective on Pacira Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, May 3rd. Wedbush reiterated an “outperform” rating and issued a $80.00 price objective on shares of Pacira Pharmaceuticals in a research report on Monday, April 30th. Cowen reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Tuesday, July 10th. Finally, Piper Jaffray Companies set a $48.00 target price on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 2nd.

In related news, CAO Kristen Marie Williams sold 2,040 shares of the company’s stock in a transaction on Monday, June 4th. The stock was sold at an average price of $33.02, for a total value of $67,360.80. Following the sale, the chief accounting officer now directly owns 19,272 shares of the company’s stock, valued at $636,361.44. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO David M. Stack sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $33.79, for a total value of $844,750.00. Following the completion of the sale, the chief executive officer now directly owns 115,446 shares in the company, valued at $3,900,920.34. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 49,093 shares of company stock worth $1,700,983. 5.90% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the stock. US Bancorp DE grew its stake in shares of Pacira Pharmaceuticals by 53.8% in the first quarter. US Bancorp DE now owns 4,292 shares of the company’s stock worth $134,000 after acquiring an additional 1,501 shares during the last quarter. Xact Kapitalforvaltning AB purchased a new stake in shares of Pacira Pharmaceuticals during the second quarter valued at $219,000. Fisher Asset Management LLC boosted its position in shares of Pacira Pharmaceuticals by 29.6% during the first quarter. Fisher Asset Management LLC now owns 6,848 shares of the company’s stock valued at $213,000 after buying an additional 1,566 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Pacira Pharmaceuticals during the second quarter valued at $312,000. Finally, Wedbush Securities Inc. purchased a new stake in shares of Pacira Pharmaceuticals during the first quarter valued at $314,000.

PCRX traded up $0.73 during midday trading on Tuesday, hitting $45.95. The stock had a trading volume of 426,519 shares, compared to its average volume of 646,402. The firm has a market cap of $1.85 billion, a P/E ratio of -79.22 and a beta of 1.83. The company has a debt-to-equity ratio of 0.98, a current ratio of 8.58 and a quick ratio of 7.79. Pacira Pharmaceuticals has a 1 year low of $26.95 and a 1 year high of $47.55.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, August 2nd. The company reported $0.24 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.37. Pacira Pharmaceuticals had a negative return on equity of 0.39% and a negative net margin of 3.64%. The firm had revenue of $84.10 million during the quarter, compared to the consensus estimate of $77.53 million. During the same quarter in the previous year, the company posted ($0.11) earnings per share. The business’s revenue was up 18.6% on a year-over-year basis. equities analysts anticipate that Pacira Pharmaceuticals will post -0.51 earnings per share for the current year.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Featured Article: Marijuana Stocks Future Looks Bright

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply